Use of Ruxolitinib Cream Results in Economic Benefits Compared with Dupilumab in Treatment of Patients with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy

Abstract Introduction Both topical and systemic treatments can be used to manage atopic dermatitis (AD) in patients with moderate AD. This study evaluates the cost of ruxolitinib cream versus dupilumab in patients with moderate AD eligible for topical or systemic therapy. Methods An economic model b...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Omar Noor, Jinan Liu, Daniel Sturm, Haobo Ren, Dilan Paranagama, Zelma C. Chiesa Fuxench, Raj Chovatiya
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Adis, Springer Healthcare 2025-11-01
Edice:	Dermatology and Therapy
Témata:	Atopic dermatitis Cost consequences Dupilumab Ruxolitinib cream
On-line přístup:	https://doi.org/10.1007/s13555-025-01602-z
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!